Category: Reports

Our Inaugural Sustainability Report 2021/2022

The Upside – EDBI E-Newsletter 2022 Q3

Presenting new developments in Q3

The Upside – EDBI E-Newsletter 2022 Q2

We continue to focus on value creation efforts for our portfolio companies.

Enhancing the development of the ASEAN markets and accelerating global market expansion for Chinese biopharma companies

Take a deep dive into the ASEAN biopharmaceutical landscape
Notice: Unauthorised use of the EDBI name and branding in Japan. EDBI officers will never solicit from the public or offer incentives for participation in our programmes. Report any incident to [email protected] if you are unsure if something is a scam.
This is default text for notification bar